Skip to main content

AHA: GLP-1 RA, SGLT-2i Use Can Lower Risk for MI, Recurrent Stroke in Stroke Survivors

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 12, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Nov. 12, 2024 -- For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are associated with reduced mortality, myocardial infarction (MI), and recurrent stroke, according to a study presented at the American Heart Association Scientific Sessions 2024, held from Nov. 16 to 18 in Chicago.

Mohammad Ali Sheffeh, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues examined the efficacy of GLP-1 RA or SGLT-2i initiation for reducing mortality or cardiovascular events among adults with ischemic stroke. Data were included for 7,044 individuals (mean age, 72 ± 14 years).

The researchers found that 6 percent of the participants had a second stroke, 6 percent had an incident MI, and 53 percent died during a median follow-up of three years. In the univariate analysis, those on an SGLT-2i/GLP-1 RA had a reduced risk for mortality, incident MI, and composite. After multivariable adjustment, these associations remained significant and were not affected by minimum time of exposure. In the multivariate analysis, SGLT-2i/GLP-1 RA use was also associated with recurrent ischemic stroke. In most sub-analyses of individual medications, all associations remained significant, except for the association between GLP-1 RA and recurrent stroke.

"The results of the study are consistent with other research about the preventive role of these medications against cardiovascular disease in people with obesity or heart failure," Sheffeh said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Most Patients Newly Diagnosed With A-Fib Do Not Receive Anticoagulants

WEDNESDAY, April 23, 2025 -- For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed anticoagulants in the year...

Age-Adjusted Ischemic Stroke Mortality Increased Since 2009

FRIDAY, April 18, 2025 -- Patterns of mortality and end-of-life care have changed among U.S. ischemic stroke patients, with increases in mortality seen across all urbanization...

Study Sheds Light on Role of Risk Factors in Young-Onset Cryptogenic Ischemic Stroke

THURSDAY, April 17, 2025 -- Traditional risk factors contribute to young-onset cryptogenic ischemic stroke (CIS) without patent foramen ovale (PFO), while nontraditional risk...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.